Development of multivalent CAR T cells as dual immunotherapy and conditioning agents

Hematopoietic stem cell transplantation (HSCT) is the only definitive cure for pediatric acute myeloid leukemia (AML). Despite adjustments in HSCT protocols and improvements in supportive care, 30% of high-risk patients who receive HSCT as part of their therapy still experience disease relapse with...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Molecular Therapy: Oncology
المؤلفون الرئيسيون:	Quenton Rashawn Bubb, Mohammad Balood, Gabe Eduardo Seir, Leah Swartzrock, Ethan Haslett, Katie Ho, Peng Xu, Saida G. Wiltz, Elena Sotillo, Tanja A. Gruber, Rebecca M. Richards, Crystal L. Mackall, Agnieszka Czechowicz
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2025-03-01
الموضوعات:	MT: Regular Issue CAR-T AML pediatric AML HSCT trispecific
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S295032992500013X

مواد مشابهة

Retrospective study to compare the outcomes of matched related donor vs matched unrelated donor in patient with acute myeloid leukaemia
حسب: Md Masoom, وآخرون
منشور في: (2024-07-01)

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
حسب: Meng Zhang, وآخرون
منشور في: (2025-01-01)

Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients
حسب: Pierre Peterlin, وآخرون
منشور في: (2023-11-01)

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
حسب: Maddalena Benetton, وآخرون
منشور في: (2022-06-01)

Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia with t(8;21)(q22;q22)/RUNX1-RUNX1T1 and Additional Cytogenetic Abnormalities
حسب: TL Gindina, وآخرون
منشور في: (2016-04-01)

BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
حسب: Jing-dong Zhou, وآخرون
منشور في: (2019-06-01)

Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
حسب: Martina Canichella, وآخرون
منشور في: (2024-10-01)

Immunotherapy in Myeloproliferative Diseases
حسب: Lukas M. Braun, وآخرون
منشور في: (2020-06-01)

A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
حسب: Roula Antoine Farah
منشور في: (2014-12-01)

A review of treatment options employed in relapsed/refractory AML
حسب: Mohamed Zakee Mohamed Jiffry, وآخرون
منشور في: (2023-12-01)

Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics
حسب: Ranjit Kumar Sahoo, وآخرون
منشور في: (2013-01-01)

Novel insights and therapeutic approaches in secondary AML
حسب: Giovanni Marconi, وآخرون
منشور في: (2024-07-01)

Morphology, Cytochemistry and Flowcytometry Immunophenotypic analysis in 82 cases of Acute Leukaemias employing the Indian Consensus screening panel and comparison with the proposed basic minimal screening panel. Experience from a tertiary care hospital
حسب: Srishti Gupta, وآخرون
منشور في: (2014-08-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
حسب: Dipesh Dave, وآخرون

Maintenance therapy for AML after allogeneic HCT
حسب: Rahul K. Nayak, وآخرون
منشور في: (2022-08-01)

SKP2 regulates TERT independently of RUNX1/ETO in AML subtypes lacking the t(8,21) translocation via CDKN1B and RB phosphorylation states
حسب: Adam Azlan, وآخرون
منشور في: (2025-10-01)

Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment
حسب: Yue Liu, وآخرون
منشور في: (2025-12-01)

Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1
حسب: Li Liu, وآخرون
منشور في: (2024-07-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
حسب: Karam Ashouri, وآخرون
منشور في: (2024-04-01)

Analysis of TCGA (The Cancer Genome Atlas) Data for Prognosis, Risk Categorization, and Survival of AML Patients Using Bioinformatics
حسب: Bhavika Rishi, وآخرون
منشور في: (2025-08-01)

CEBPA mutation in acute myeloid leukemia: prognostic impact of bZIP domain mutation
حسب: Roy Raj, وآخرون
منشور في: (2024-10-01)

Fluorescence in situ hybridization analysis of the hTERC region in acute myeloid leukemia patients
حسب: Özge Özer, وآخرون
منشور في: (2011-05-01)

The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review
حسب: Mobina Nakhaei Shamahmood, وآخرون
منشور في: (2025-10-01)

The giant within: A rare case of bilateral renal angiomyolipoma surpassing 30 cm
حسب: Hadj Hsain ihssan, وآخرون
منشور في: (2025-04-01)

Osteolytic bone lesions – A rare presentation of AML M6.
حسب: Geetha N., وآخرون
منشور في: (2015-02-01)

Concurrent hyperdiploid acute myeloid leukemia and trisomy 12+ chronic lymphocytic leukemia
حسب: Tulasi Geevar, وآخرون
منشور في: (2024-10-01)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
حسب: Mustafa Nissar Bankur, وآخرون
منشور في: (2022-06-01)

Anti-angiogenic activity of ShengMaBieJia decoction in vitro and in acute myeloid leukaemia tumour-bearing mouse models
حسب: Mengya Wang, وآخرون
منشور في: (2020-01-01)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
حسب: Olga K. Weinberg, وآخرون
منشور في: (2023-08-01)

Cytogenetics and molecular markers of acute myeloid leukemia from a tertiary care center in Saudi Arabia
حسب: Abdulaziz I Alrajeh, وآخرون
منشور في: (2017-01-01)

Granulocytic sarcoma of finger: a case report
حسب: Aysin Purbager, وآخرون
منشور في: (2016-03-01)

Case report: NUP98::LEDGF fusion gene drives malignant hematological tumor with mixed immunological phenotype
حسب: Song Xue, وآخرون
منشور في: (2024-09-01)

Unveiling sentiments of the cullen commission: Exploring AML compliance and regulation through deep learning techniques
حسب: Mark E. Lokanan
منشور في: (2025-03-01)

Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
حسب: Scott Auerbach, وآخرون
منشور في: (2024-02-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
حسب: Andrea Duminuco, وآخرون
منشور في: (2022-09-01)

CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML
حسب: Esmaeil Shahabi Satlsar, وآخرون
منشور في: (2020-11-01)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
حسب: Davidson Zhao, وآخرون
منشور في: (2023-03-01)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
حسب: Xing-yu Cao, وآخرون
منشور في: (2023-12-01)

Fluorescence in situ hybridization analysis of the hTERC region in acute myeloid leukemia patients
حسب: Özge Özer, وآخرون
منشور في: (2011-06-01)

Successful management of granulocytic sarcoma with concurrent hemophagocytic lympho histiocytosis in a child
حسب: Yogiraj Chopra, وآخرون
منشور في: (2016-10-01)